|
Yale Cancer Center NCTN
|
5U10CA180826-05
|
$700,035
|
$35,002
|
FUCHS, CHARLES
|
YALE UNIVERSITY
|
|
Winship Cancer Institute, National Clinical Trials Network Lead Academic Particip
|
5U10CA180864-05
|
$542,950
|
$20,361
|
RAMALINGAM, SURESH
|
EMORY UNIVERSITY
|
|
Vanderbilt Network Lead Academic Participating Site for the NCTN
|
5U10CA180847-06
|
$503,410
|
$25,171
|
BERLIN, JORDAN
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
|
5U10CA180870-05
|
$644,932
|
$16,123
|
GERBER, DAVID
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
|
5U10CA180858-05
|
$1,267,600
|
$31,690
|
ENG, CATHY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
3P30CA014089-43S1
|
$40,593
|
$406
|
FARNHAM, PEGGY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
5P30CA014089-43
|
$6,268,475
|
$62,685
|
FARNHAM, PEGGY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Urologic Oncology Research Training Grant
|
5T32CA082088-19
|
$302,547
|
$45,382
|
CARVER, BRETT
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Urologic Oncology Branch Consult Core
|
ZID BC 011092
|
$1,540,531
|
$154,053
|
Linehan, W. Marston
|
CCR (NCI)
|
|
University of Hawaii Cancer Center CCSG
|
2P30CA071789-18
|
$1,913,800
|
$133,966
|
HOLCOMBE, RANDALL
|
UNIVERSITY OF HAWAII AT MANOA
|
|
University of Colorado NTCN Lead Academic Participating Site (LAPS)
|
5U10CA180834-05
|
$768,950
|
$38,448
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities
|
1U54CA233306-01
|
$6,160,778
|
$800,901
|
PAN, CHONG-XIAN
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
Understanding the AGL metastasis suppressor for therapeutic gain
|
3R01CA143971-08S1
|
$149,644
|
$149,644
|
THEODORESCU, DAN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Understanding the AGL metastasis suppressor for therapeutic gain
|
7R01CA143971-08
|
$481,438
|
$481,438
|
THEODORESCU, DAN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Understanding barriers to single-dose intravesical chemotherapy in non-muscle invasive bladder cancer
|
5K23CA212272-03
|
$144,313
|
$144,313
|
CARY, KELLY
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
UM LAPs- U10 Grant
|
5U10CA180801-05
|
$763,048
|
$38,152
|
ZALUPSKI, MARK
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles
|
1R43CA232778-01
|
$295,240
|
$295,240
|
ASSOULINE, JOE
|
NANOMEDTRIX, LLC
|
|
UCDCCC NCTN U10 Program
|
5U10CA180846-05
|
$623,007
|
$15,575
|
GANDARA, DAVID
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
Translational Surgical Pathology
|
ZIE SC 000853
|
$183,408
|
$12,839
|
Merino, Maria
|
CCR (NCI)
|
|
Translation of a Clinical Molecular Diagnostic Assay for Bladder Cancer
|
5R01CA206584-02
|
$620,469
|
$620,469
|
GOODISON, STEVE
|
MAYO CLINIC JACKSONVILLE
|
|
Towards a non-invasive molecular test for bladder cancer
|
5R01CA116161-09
|
$373,690
|
$373,690
|
GOODISON, STEVE
|
MAYO CLINIC JACKSONVILLE
|
|
Tobacco Companies, Public Policy and Global Health
|
5R01CA091021-15
|
$95,386
|
$4,769
|
LEE, KELLEY
|
SIMON FRASER UNIVERSITY
|
|
Tissue Processing-Sequencing Facility
|
ZIC BC 011044
|
$648,792
|
$64,879
|
Vocke, Cathy
|
CCR (NCI)
|
|
The Incidence of Breast and other Cancers among Female Flight Attendants
|
ZIA CP010133 04077
|
$16,720
|
$334
|
Little, Mark
|
DCEG (NCI)
|
|
TAS::75 0849::TAS ADMINISTRATIVE MODIFICATION
|
261200800001E
|
$313,286,406
|
$64,039
|
DMITROVSKY, ETHAN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
Targeting the MET pathway in urothelial carcinoma
|
ZIA BC 011594
|
$497,661
|
$497,661
|
Apolo, Andrea
|
CCR (NCI)
|
|
Targeting Metabolic Pathways in Bladder Cancer
|
ZIA BC 011741
|
$154,179
|
$154,179
|
Agarwal, Piyush
|
CCR (NCI)
|
|
Targeting mechanisms of radiation resistance
|
ZIA BC 011552
|
$472,836
|
$236,418
|
Citrin, Deborah
|
CCR (NCI)
|
|
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
|
5U01CA217858-02
|
$1,314,469
|
$262,894
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
SWOG Statistics and Data Management Center
|
5U10CA180819-05
|
$7,938,884
|
$158,778
|
LEBLANC, MICHAEL
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
SWOG Network Group Operations Center of the NCTN
|
3U10CA180888-05S1
|
$670,913
|
$13,418
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
SWOG Network Group Operations Center of the NCTN
|
5U10CA180888-05
|
$8,625,592
|
$172,512
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Subtyping Bladder Cancer: A Multi-omic, Exposure-informed, Genealogical Approach (MErGE)
|
1K07CA230150-01
|
$149,405
|
$149,405
|
HANSON, HEIDI
|
UNIVERSITY OF UTAH
|
|
Statistics and Data Center for the Alliance for Clinical Trials in Oncology
|
5U10CA180882-05
|
$8,303,242
|
$166,065
|
MANDREKAR, SUMITHRA
|
MAYO CLINIC ROCHESTER
|
|
Stanford University NCTN- Network Lead Academic Site
|
5U10CA180816-05
|
$518,824
|
$12,971
|
WAKELEE, HEATHER
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
$2,485
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
$1,715
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
$33,345
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
SPORE in Genitourinary Cancer
|
3P50CA091846-15S1
|
$1,162,609
|
$1,162,609
|
DINNEY, COLIN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
SPORE in Bladder Cancer
|
1P50CA221745-01A1
|
$2,299,837
|
$2,299,837
|
BAJORIN, DEAN
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Signal Transduction Events and the Regulation of Cell Growth
|
ZIC SC 006743
|
$553,334
|
$55,333
|
Trepel, Jane
|
CCR (NCI)
|
|
SESN2 and therapeutic effect of Isohapontigenin (ISO)
|
1R01CA217923-01A1
|
$422,057
|
$422,057
|
HUANG, CHUANSHU
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Screening to identify protectors and mitigators of Radiation GI Syndrome
|
ZIA BC 011762
|
$472,836
|
$189,134
|
Citrin, Deborah
|
CCR (NCI)
|
|
SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.
|
5R44CA200174-03
|
$670,314
|
$670,314
|
LEVIN, TREVOR
|
UROLOGY DIAGNOSTICS, INC.
|
|
Role of Shh in developmental patterning and growth of digit skeleton
|
ZIA BC 011118
|
$320,272
|
$32,027
|
Mackem, Susan
|
CCR (NCI)
|
|
Role of histone kinase VprBP in gene silencing: mechanisms, targets, and regulation
|
5R01CA201561-03
|
$377,438
|
$124,555
|
AN, WOOJIN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Role of APOBEC3B in Epigenetic Regulation and Transformation in Cancer
|
1F32CA232458-01
|
$58,654
|
$19,356
|
LEVIN-KLEIN, RENA
|
UNIVERSITY OF MINNESOTA
|
|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$911,727
|
N/A
|
National Institutes of Health
|
|
Regulation of Urinary Bladder Carcinogenesis and Progression by SPARC
|
5R01CA193437-03
|
$354,563
|
$354,563
|
SAID, NEVEEN
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
Regulation of ATDC by TP63 and its role in bladder cancer
|
5K08CA201335-03
|
$174,960
|
$174,960
|
PALMBOS, PHILLIP
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
Total relevant funding to Bladder for this search: $40,443,790
|